

CADTH DRUG REIMBURSEMENT REVIEW

Pharmacoeconomic Report

ATEZOLIZUMAB (TECENTRIQ)

(Hoffman-La Roche Limited)

Indication: In combination with bevacizumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma who require systemic therapy.

Version: Final

Publication Date: November 17, 2020

Report Length: 16 Pages

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

List of Tables	4
Abbreviations	5
Executive Summary	6
Conclusions	8
Stakeholder Input Relevant to the Economic Review	9
Economic Review	10
Appendix 1: Cost Comparison Table	11
Appendix 2: Submission Quality	12
Appendix 3: Additional Information on the Submitted Economic Evaluation	13
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation	14
Appendix 5: Submitted BIA and CADTH Appraisal	15

List of Tables

Table 1: Submitted for Review.....	6
Table 2: Summary of Economic Evaluation.....	7

Abbreviations

BCLC	Barcelona Clinic liver cancer
CDR	CADTH Common Drug Review
EQ-5D-5L	EuroQoL-Five Dimension-5-Level
HCC	hepatocellular carcinoma
ICER	incremental cost-effectiveness ratio
LY	life-year
NMA	network meta-analysis
NOC	notice of compliance
PSM	partitioned-survival model
QALY	quality-adjusted life year
SoC	standard of care

Executive Summary

The executive summary is comprised of two tables (Table 1: Background and Table 2: Economic Evaluation) and a conclusion.

Table 1: Submitted for Review

Item	Description
Drug product	Atezolizumab (Tecentriq), 60 mg / mL vial in combination with bevacizumab 100 mg or 400 mg vials for intravenous infusion.
Submitted price	Atezolizumab, 1200 mg / 20 mL, intravenous infusion: \$6,776.00 per vial
Indication	Atezolizumab in combination with bevacizumab for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
Health Canada approval status	NOC
Health Canada review pathway	Standard review
NOC date	August 7, 2020
Reimbursement request	Atezolizumab in combination with bevacizumab, for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Maintenance on either atezolizumab or bevacizumab should continue until loss of clinical benefit or unacceptable toxicity.
Sponsor	Hoffmann-La Roche Limited.
Submission history	<p>Previously reviewed: Yes</p> <p>Non-Small Cell Lung Cancer: Indication: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on or after systemic chemotherapy until loss of clinical benefit Recommendation date: June 20, 2018 Recommendation: Reimburse under the following conditions: (i) cost-effectiveness being improved to an acceptable level; and (ii) the drug plan cost of treatment with atezolizumab should not exceed the public drug plan cost of treatment with the least costly alternative immunotherapy.</p> <p>Small Cell Lung Cancer: Indication: For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance with atezolizumab should be continued until loss of clinical benefit or unacceptable toxicity. Recommendation date: January 30, 2020 Recommendation: Do not reimburse.</p> <p>Advanced or Metastatic Triple-Negative Breast Cancer: Recommendation: withdrawn by the sponsor on February 12, 2020</p> <p>Non-Squamous Non-Small Cell Lung Cancer: Indication: For the treatment of metastatic EGFR and/or ALK positive non-squamous non-small cell lung cancer in patients who have progressed on treatment with targeted therapies. Maintenance atezolizumab should be continued until loss of clinical benefit or unacceptable toxicity. Maintenance bevacizumab should be continued until disease progression or unacceptable toxicity. Recommendation: Do not reimburse.</p>

HCC = hepatocellular carcinoma; mg = milligram; mL = milliliter NOC = Notice of Compliance

Table 2: Summary of Economic Evaluation

Component	Description
Type of economic evaluation	Cost-utility analysis Partitioned survival model (PSM)
Target population	Adult patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy
Treatment	Atezolizumab in combination with bevacizumab
Comparators	Standard of care (SoC) consists of sorafenib or lenvatinib
Perspective	Canadian publicly funded health care payer
Outcomes	Quality-adjusted life-years (QALYs); Life-Years (LYs)
Time horizon	Lifetime (10 years)
Key data source	IMbrave150 phase III, open-label trial reporting overall survival (OS) and progression-free survival (PFS) for atezolizumab in combination with bevacizumab, compared with sorafenib. Comparative efficacy of atezolizumab plus bevacizumab compared with lenvatinib was obtained from a network meta-analysis (NMA) that reported hazard ratios for the relative treatment effects for OS and PFS.
Submitted results for base case (and key scenario analyses as required)	The sequential ICER for atezolizumab plus bevacizumab was: <ul style="list-style-type: none"> Atezolizumab plus bevacizumab vs lenvatinib: \$328,622 per QALY (2.07 incremental QALYs, \$332,281 incremental costs).
Key limitations	<ul style="list-style-type: none"> Several issues were identified with the extrapolation of the clinical efficacy data within the submitted economic evaluation. As OS data was not mature there was uncertainty regarding extrapolations beyond final data cut-offs in the trial. Clinical experts noted that the sponsor's chosen extrapolated curves were highly optimistic leading to significant long-term survival gains with no evidence to substantiate these claims. The comparative efficacy of atezolizumab plus bevacizumab and lenvatinib is associated with uncertainty. The NMA used data from populations that may not be comparable and excluded key comparators and trials. The NMA-derived estimates were informed by a sparsity of data and wide credible intervals around the estimates may have contributed to greater imprecision. Therefore, the magnitude of the clinical benefit of atezolizumab plus bevacizumab versus lenvatinib is uncertain. Uncertainty exists as to the elicitation of utility values. The sponsor used a regression analysis to determine treatment-specific utility weights that accounted for progression status and the occurrence of adverse events without sufficient description of the methods. This deviates from best practice guidelines that recommend utility weights be based on health states. Furthermore, ongoing treatment may be a stronger predictor of quality of life than progression indicated by patients' willingness to remain on treatment despite progression, and the full impact of acute or severe adverse events would not be captured in routine utility questionnaires. The proportion of patients receiving subsequent therapy was not representative of Canadian clinical practice, with fewer patients on atezolizumab plus bevacizumab receiving subsequent therapy than patients on sorafenib or lenvatinib. According to clinical experts and published real world evidence, patients treated with sorafenib received subsequent treatment at a similar proportion to patients treated with atezolizumab plus bevacizumab. Total drug acquisition costs of sorafenib may have been overestimated due to the sponsor's choice of the time-to-off-treatment parametric curve applied in the base case.
CADTH reanalysis results	<ul style="list-style-type: none"> CADTH conducted a reanalysis which included: selecting alternative parametric survival distributions for OS and PFS for atezolizumab plus bevacizumab, and OS for sorafenib; applying health state utilities based on patients being on or off treatment and removing treatment specific utilities; assuming an equal proportion of patients receive subsequent therapy regardless of first-line treatment; and, selecting an alternative parametric survival distribution for time-to-off treatment with sorafenib. Based on CADTH reanalyses, the sequential ICER for atezolizumab plus bevacizumab versus sorafenib is \$771,970 per QALY;

Component	Description
	<ul style="list-style-type: none"> At a price reduction of 99% for atezolizumab, the ICER for atezolizumab plus bevacizumab is \$309,306 per QALY gained. It is highly unlikely that atezolizumab plus bevacizumab would be considered cost-effective at a conventionally accepted ICER threshold (\$50,000), unless there were significant price reductions for both atezolizumab and bevacizumab.

HCC = hepatocellular carcinoma; ICER = incremental cost-effectiveness ratio; LY = life-year; NMA = network meta-analysis; OS = overall survival; PSM = partitioned survival model; SoC = standard of care; QALY= quality-adjusted life-year.

Conclusions

CADTH undertook reanalyses of the sponsor’s economic submission to address some of the identified limitations. The changes which had the largest impact on the model results included selecting alternative parametric survival distributions for OS and PFS for atezolizumab plus bevacizumab. Based on CADTH reanalyses, the sequential ICER for atezolizumab plus bevacizumab compared to lenvatinib was \$771,970 per QALY gained. The results are primarily driven by the combined cost of treatment for atezolizumab plus bevacizumab. With a 99% price reduction for atezolizumab, the ICER decreases to \$309,306 per QALY, exceeding \$50,000 per QALY, as the cost of bevacizumab remains high.

Overall, it is highly unlikely that atezolizumab plus bevacizumab would be considered a cost-effective use of Canadian healthcare resources, at a \$50,000 per QALY threshold, even if substantial price reductions were obtained for both atezolizumab and bevacizumab.

Based on the sponsor’s submitted budget impact analysis, the total incremental budget impact is estimated to be \$██████████ over the first three years. CADTH reanalyses suggest that the estimated budget impact of introducing atezolizumab plus bevacizumab would be similar at \$199,200,041 over three years. *(Non-disclosable information was used in this CADTH Guidance Report and the sponsor requested this economic information not be disclosed pursuant to the Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review. This information will remain redacted until notification by the sponsor that it can be publicly disclosed).*

Stakeholder Input Relevant to the Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 1: Cost Comparison Table

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 2: Submission Quality

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 3: Additional Information on the Submitted Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 5: Submitted BIA and CADTH Appraisal

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

References

1. Primary Clinical Study Report: YO40245 (IMbrave150). A phase III, openlabel, randomized study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma [internal sponsor's report]. In: pan-Canadian Oncology Drug Review sponsor submission: Tecentriq (atezolizumab) concentrate for solution for infusion, 60 mg/mL, 1200 mg/20 mL and 840 mg/14 mL single use vials. Mississauga (ON): Hoffmann-La Roche; 2020.
2. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review sponsor submission: Tecentriq (atezolizumab) concentrate for solution for infusion, 60 mg/mL, 1200 mg/20 mL and 840 mg/14 mL single use vials. Mississauga (ON): Hoffmann-La Roche; 2020.
3. Exceptional Access Program: Drug Benefit Prices. Toronto (ON): Ministry of Health; Ministry of Long-term Care; 2020: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx. Accessed 2020 Sep 21.
4. Schedule of benefits for physician services under the Health Insurance Act: effective April 1, 2020. Toronto (ON): Ontario Ministry of Health; 2020: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physsserv/sob_master20200306.pdf. Accessed 2020 Jun 18.
5. Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. *J Palliat Care*. 2011;27(2):79-88.
6. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa (ON): CADTH; 2017: <https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition>. Accessed 2020 Jun 18.
7. Fung AS, Tam VC, Meyers DE, et al. Second-line treatment of hepatocellular carcinoma after sorafenib: characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab. *Cancer Med*. 2020;9(13):4640-4647.
8. DeltaPA. [Ottawa (ON)]: IQVIA; 2020: <https://www.iqvia.com/>. Accessed 2020 Jun 30.
9. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020;382(20):1894-1905.
10. PrLenvima® (levatinib): 4mg and 10mg capsules [product monograph]. Mississauga (ON): Eisai; 2018 Dec 19: https://pdf.hres.ca/dpd_pm/00048812.PDF. Accessed 2020 Jun 18.
11. Budget Impact Analysis. In: pan-Canadian Oncology Drug Review sponsor submission: Tecentriq (atezolizumab) concentrate for solution for infusion, 60 mg/mL, 1200 mg/20 mL and 840 mg/14 mL single use vials. Mississauga (ON): Hoffmann-La Roche; 2020.
12. Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. *J Gastroenterol*. 2020;55(1):113-122.
13. Hoffmann-La Roche response to additional pCODR checkpoint meeting questions on Tecentriq (atezolizumab) and Avastin (bevacizumab) for the treatment of hepatocellular carcinoma. Mississauga (ON): Hoffmann-La Roche; 2020 Aug 6.